Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

NCT02955888 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped Unsatisfactory rate of recruitment

Conditions

Cystic Fibrosis

Interventions

DRUG: PBI4050
DRUG: Placebo

Sponsor

Liminal BioSciences Ltd.